Kornimate/medical-research-clean huggingface dataset:
effects of inspiratory muscle training after lung cancer surgery, a randomized controlled trial

Conditions: Lung Cancer; Surgery

Summary: the purpose of this study is to evaluate the effects of postoperative inspiratory muscle training on the recovery of respiratory muscle strength in high risk patients referred for lung cancer surgery. furthermore, to assess longitudinal changes in respiratory muscle strength, physical capacity and health-related quality of life after lung cancer surgery

advances in early detection and treatment improve life expectancy after surgery for lung cancer, but living with lung cancer is frequently associated with symptoms as dyspnoea, decreased physical capacity and fatigue several years after treatment. lung cancer (lc) surgery is associated with a high incidence of postoperative pulmonary complications (ppc), having a negative impact on recovery. although the causes of ppc are multifactorial, respiratory muscle (rm) dysfunction has been proposed to be associated with the development of ppc, explained by changes in rm mechanics- and function due to surgery. there is scarcity of literature on the impact of rm dysfunction on surgical and functional outcomes after lc surgery. aims: to describe longitudinal changes in rm strength in patients undergoing lung cancer surgery and identify associations between rm strength and functional capacity. furthermore, to evaluate the effect of inspiratory muscle training on the recovery of respiratory muscle strength in high risk patients referred for lc surgery. target population: 88 patients referred for lung cancer surgery at the department of cardiothoracic surgery, aalborg universityhospital. design: the core of this research is a prospective longitudinal observational study (study 1); included is a randomized controlled trial, based on a subpopulation from study 1. statistical analysis is based on mixed linear regression models and anova. for the rct we use the generalized estimating equivalent method for parametric and fisher´s exact test for nonparametric data.

Eligibility criteria:
inclusion criteria: * age \>18 years; scheduled for thoracic surgery on the suspicion/confirmed lung tumor via open thoracotomy or visual assisted thoracotomy(includes primary lung cancer, metastases from other cancer sites without activity within none year, other tumor types requiring resection of lung tissue; furthermore, for rct, one of the following: age ≥ 70 years or fev1 ≤ 70% predicted or dlco ≤ 70% predicted or scheduled pneumonectomy) exclusion criteria: * physical or mental deficits that adversely influence physical performance; can neither speak nor read danish; previous ipsilateral lung resection; tumor activity in other sites or organs; pancoast tumor

Keywords: lung cancer surgery inspiratory muscle training postoperative pulmonary complications functional outcomes health related quality of life
effectiveness of resistive capacitive diathermy in patients affected by knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: it is a double-blind randomized sham-controlled clinical trial to evaluate the effectiveness of resistive capacitive diathermy in subjects affected by knee osteoarthritis in comparison with a "sham" diathermy treatment. the resistive capacitive diathermy is a medical device supplying low (448 khz) radiofrequencies with maximum output power of 200 w, used to reduce pain and inflammation and allowing healing processes. the sham diathermy treatment is administered with the device set on "on" but not active (not supplying energy). each subject, randomly assigned to either resistive capacitive diathermy treatment (group 1) or sham-treatment (group 2) is submitted to a thirty minutes session, three times per week for a total of ten sessions. the outcome measures are the womac scale (western ontario and mcmaster universities arthritis index) to assess pain and physical functioning, a visual analogic scale (vas) for pain, the femoral quadriceps strength (mrc = medical research council scale). outcome measures are administered at baseline (t0), at the end of the treatment protocol (t1), at 1 month (t2) and 3 months (t3) after the end of treatment.


Eligibility criteria:
inclusion criteria: * patients affected by knee osteoarthritis established by clinical examination and x-ray in postero-anterior and lateral views exclusion criteria: * neurologic disorders involving the lower limbs * systemic inflammatory disorders * pace-maker implantation * severe heart disease * acute infections or bone tuberculosis * acute skin diseases * history of surgery on the affected knee * cognitive or psychiatric disorders

Keywords: physical therapy diathermy knee osteoarthritis pain physical function
patient education on labor analgesia options

Conditions: Labor Analgesia

Summary: the purpose of this study is to learn how the investigators can better educate pregnant patients about the options open to them for pain relief during labor. patients will receive educational pamphlet during prenatal clinic visit and again on admission to labor and delivery. the options for analgesia will be discussed by anesthesia care provider. patient will be asked to complete a survey on the post partum unit.

many analgesic options exist for laboring parturients, but labor may not be the best time to start informing patients of their options. many patients begin the labor process with a plan in place for their analgesia. unfortunately, internet resources regarding labor analgesia that are available to the lay parturient are poor and often lead to misconceptions about the options and their risks. a significant number of patients refuse neuraxial analgesia based on misunderstandings, concerns about the procedure, or a lack of faith in the provider. some women want a "natural childbirth" and/or control over their labor experience. our study aimed at providing information and alternatives for labor analgesia in a simple written format. the investigators will provide information of available labor analgesia options (epidural, combined spinal/epidural, spinal, remifentanil patient-controlled analgesia, and intravenous opioids) to expecting mothers. using a pamphlet written in english or spanish disseminated to pregnant women in clinic and upon arrival in the labor and delivery unit, the procedures and their risks and benefits will be explained in simple terms. in the labor and delivery unit the patients will have an opportunity to ask questions of the anesthesia care giver regarding the options for analgesia. after delivery while on f green, patients will be asked to complete a questionnaire addressing their thoughts about the pamphlets and their overall satisfaction with their labor analgesia. the analysis will focus on the utility and effect of education materials on maternal informed consent for labor analgesia, on maternal choice of analgesia modality, and on maternal anxiety regarding their labor analgesia plan.

Eligibility criteria:
inclusion criteria: * postpartum women ages 18 and older * patients who speak and read english or spanish * patients who received our informational pamphlet while pregnant or in labor * patients who are able to consent and make medical decisions * patients undergoing labor or trial of labor after cesarean delivery * patients who undergo cesarean delivery after trial of labor exclusion criteria: * patients unable or unwilling to complete questionnaire * patients unable to consent or make medical decisions * patients less than 18 years of age * patients unable to read and speak english or spanish * patients in whom any of the analgesic options were contraindicated * patients with a history of an anxiety disorder * patients with precipitous labor or late presentation that precluded an analgesic intervention * patients with fetal distress that precluded an analgesic intervention * patients planned for elective cesarean section.
unsaturated fatty acids to improve cardiorespiratory fitness in obesity and hfpef

Conditions: Obesity; Heart Failure With Normal Ejection Fraction

Summary: this study is designed to evaluate the effects of a diet rich in unsaturated fatty acids (ufa)-also known as 'healthy fats'-in patients with obesity and heart failure with preserved ejection fraction (hfpef) on dietary consumption of ufa as well as fatty acids plasma levels.

the study will evaluate participant's food consumption during 2 different 12-week periods. during one of the 12-week periods, participants will receive specific counseling and instructions on how to increase the consumption of food rich in healthy fats; during the other 12-week period they will receive general dietary recommendations following the dietary guidelines for americans. there will be a 6-week break (washout) between the 12-week periods for a total of study period of 30 weeks. during each 12-week periods, the study will measure the effects of these dietary recommendations on dietary consumption and the fatty acids in their blood (primary endpoints).

Eligibility criteria:
major inclusion criteria: * body mass index (bmi) ≥30 kg/m2 (obesity) or total body fat percentage \>25% in men and \>35% in women * a confirmed clinical diagnosis of stable hf (new york heart association (nyha) class ii-iii) on maximally tolerated heart failure (hf) optimal medical regimen (without major changes in the prior month) * left ventricular ejection fraction (lvef)\>50% documented in the prior 12 months major exclusion criteria: * concomitant conditions or treatment which would affect completion or interpretation of the study (i.e.,physical inability to walk or run on treadmill); * significant ischemic heart disease, angina, uncontrolled arterial hypertension, atrial fibrillation, moderate to severe valvular disease, chronic pulmonary disease, anemia (hemoglobin\<10 g/dl) * electrocardiography (ecg) changes (ischemia or arrhythmias) that limit maximum exertion during cardiopulmonary exercise test * comorbidity limiting survival * stage iv-v kidney disease (estimated glomerular filtration rate\<30) * fluid overload * pregnancy * current use of unsaturated fatty acids (ufa) supplement (i.e., omega-3). * inability to give informed consent

Keywords: obesity heart failure with normal ejection fraction hfpef unsaturated fatty acids cardiorespiratory fitness dietary intervention
solifenacin succinate with tamsulosin hcl in males with lower urinary tract symptoms and bladder outlet obstruction

Conditions: Lower Urinary Tract Symptoms; Bladder Outlet Obstruction

Summary: a study to evaluate the safety of the co-administration of solifenacin succinate with tamsulosin hydrochloride in men with lower urinary tract symptoms (luts) and bladder outlet obstruction (boo).


Eligibility criteria:
inclusion criteria: * diagnosed with lower urinary tract symptoms (luts) and bladder outlet obstruction (boo) * boo indication by a bladder outlet obstruction index (booi) ≥ 20 * patient has a total international prostate symptom score (ipps) score of ≥ 8 (inclusion criteria for baseline also) * patient had a maximum urinary flow rate of ≤ 12 ml/sec, with a voided volume of ≥ 120 ml during free flow in a representative assessment of uroflowmetry. exclusion criteria: * history of urinary retention in preceding 12 months * current urinary tract infection (uti) or symptomatic and recurrent uti of \> 3 episodes within 12 months. * known clinical history or diagnosis of chronic inflammation, stone in bladder or ureter, or other causes of outflow tract obstruction * known diagnosis or history of carcinoma or previous pelvic radiation therapy, except non-metastatic basal or squamous cell carcinoma of the skin that had been treated successfully * clinically significant cardiovascular or cerebrovascular diseases within 6 months prior to visit 1

Keywords: lower urinary tract symptoms bladder outlet obstruction treatment solifenacin succinate tamsulosin hydrochloride
retrospective study collecting neurological follow-up of hereditary transthyretin amyloidosis (attrv) patients included in b3461028 and b3461045.

Conditions: Hereditary Transthyretin Amyloidosis (ATTRv); Polyneuropathy

Summary: a study of patients with hereditary transthyretin amyloidosis (attrv) and wild-type transthyretin amyloidosis (attrwt) that have been enrolled in b3461028 and b3461045 studies in spain - exposed to tafamidis 61mg for ≥12 months with polyneuropathy (pn) have kept going to their multisystemic follow-ups (neuro/ophthalmo/gastrointestinal) ≥12 months.


Eligibility criteria:
inclusion criteria: * treatment with tafamidis 61 mg ≥ 12 months * neurological follow up ≥ 12 months * diagnosis of transthyretin amyloidosis with polyneuropathy (attr-pn) based on one of the following: * amplitude reduction in, at least, 2 nerves under normal value, excluding median nerve or 50% amplitude reduction in, at least, 2 nerves on the basal value of the patient, excluding median nerve or 2 abnormal tests detecting thin fibers alterations (through sudo scan, rr interval analysis, etc..) exclusion criteria: * treatment with tafamidis 61 mg \< 12 months * neurological follow up \< 12 months * other diagnosis for polyneuropathy
individualized locoregional treatment of initially biopsy-proven node-positive breast cancer after primary systemic therapy

Conditions: Breast Cancer

Summary: in clinically node-positive (cn+) breast cancer, preoperative systemic therapy (pst) is common. with increasing rates of complete tumour eradication, there is a need for de-escalation of locoregional treatment in the interest of decreased morbidity. in order to individually adapt postoperative therapies, axillary staging is crucial. axillary lymph node dissection (alnd) comes at a high risk of arm morbidity. there is extreme divergence in the use of less extensive staging methods, i.e. targeted lymph node biopsy (tlnb), sentinel node biopsy (snb) or both (tad), and in the use of subsequent locoregional treatment, since prospective data are largely lacking. the main purpose of the european indax trial is to implement de-escalated staging and evaluate which regional treatment, individually adapted to the response after pst, is oncologically safe but least harmful. population: cn+ breast cancer patients receiving pst, recruited 2021-2025. staging by tlnb, tad or snb. intervention: negative staging (ypn0, randomisation a, n=1433): no regional treatment. positive staging (ypn+, randomisation b, n=1513): no alnd but regional radiotherapy (rrt). control: randomisation a: rrt only. randomisation b: alnd plus rrt. outcome: invasive disease-free survival (non-inferiority), arm morbidity and quality of life. drug tests in whole-tumour organoid cultures, algorithm-based digital image analysis and gene expression analysis are performed to improve response prediction, facilitate tailoring of pst and increase eradication rates.


Eligibility criteria:
inclusion criteria: * patients with primary invasive breast cancer ct1-ct3 * cn1 status prior to pst * cytological or histological proof of axillary metastasis before pst * full tumour biology available before initiation of pst * oral and written consent * age ≥ 18 years exclusion criteria: * biopsy-confirmed regional nodal metastases outside of the ipsilateral axilla * distant metastases at diagnosis * inflammatory breast cancer * previous axillary surgery * previous radiotherapy to ipsilateral breast, chest or axilla * history of prior invasive breast cancer * ongoing pregnancy or breast-feeding * bilateral invasive breast cancer * medical contraindication for radiotherapy or inability to receive recommended radiotherapy * medical contraindication for adjuvant endocrine treatment, if indicated * inability to absorb or understand the meaning of the study
acute effect of hmg-coa reductase inhibition (atorvastatin)on renal hemodynamics, tubular function and vasoactive hormones on healthy subjects

Conditions: Healthy

Summary: we wanted to test the acute effect of hmg-coa reductase inhibition (atorvastatin) on renal hemodynamics, renal tubular function and vasoactive hormones on healthy subjects.


Eligibility criteria:
inclusion criteria: * both men and women * age: between 20-50 * bmi\<30 exclusion criteria: * clinical signs or history of disease of heart, lungs, kidneys or endocrine organs. * abnormal lab. tests( haemoglobin, pl. sodium, pl. potassium, pl.creatinine, pl.bilirubin, pl.alat, pl. cholesterol, blood glucose) * albuminuria or glucosuria * cancer * art. hypertension * alcohol abuse * medical treatment, except oral contraceptives * pregnancy or breast feeding * blood donation less than 1 month before study

Keywords: hmg-coa reductase inhibition gfr rpf fe cl
regulation of lncrna for breg in patients with thymoma and autoimmune diseases

Conditions: Thymoma; Autoimmune Disease

Summary: initially investigators will find lncrna which to be able to affect notch2 signaling pathway; then confirm the relationship between notch2 and lncrna, and analysis the regulation mode of lncrna to notch2 signaling pathway, and to observe the correlation between lncrna and thymoma complicated with autoimmune diseases.

1. this study plans to research the correlation between bregs and thymoma complicated with autoimmune diseases and the regulation the severity of the disease. 2. clarify different expression levels of notch2 signaling pathway in thymoma complicated with autoimmune diseases, and the effect on regulatory b cells(bregs). 3. find the effective regulation mode of notch2 signaling pathway and the regulation of bregs cell development and function in lncrna.

Eligibility criteria:
inclusion criteria: * (1) the patients with the diagnosis of mediastinal tumors (thymoma, thymic hyperplasia); (2) the patients with the diagnosis of autoimmune diseases; (3) age of 18 years or older which expected to stay in icu for≥5 days. (4) apache ii score \> 15; (5) the patients or authorized clients agree to participate in the clinical trial and sign the informed consent. exclusion criteria: * (1) the patients with circulatory, respiratory failure and major organ dysfunction after being endangered and transferred to icu; (2) patients with severe liver and renal dysfunction; (3) pregnant or lactating women; (4) patients who have not signed the informed consent; (5) any factors that may be expected to increase the risk of patients or other factors that may interfere with the outcome of clinical trials.

Keywords: long non-coding rna（lncrna） thymoma autoimmune disease notch2 signaling pathway regulatory b cell（breg）
cortical excitability and role of rtms in nicotine use disorder

Conditions: Nicotine Use Disorder

Summary: cortical excitability and role of repetitive transcranial magnetic stimulation in nicotine use disorder. estimation of cortical excitability in heavy smoker patients and determination of role of repetitive transcranial magnetic stimulation for reducing nicotine craving.

nicotine is one of the main components of cigarettes and affects the central nervous system mainly via nicotinic acetylcholine receptors. it has further effects on neuromodulation by regulating the release of dopamine, serotonin, glutamate and adrenaline. in studies, it has been shown that nicotine improves attention and working memory in animals and humans, while nicotine withdrawal leads to reduced working and verbal memory capacity in otherwise healthy tobacco smokers. in schizophrenics and patients suffering from attention deficit hyperactivity disorder, nicotine improves cognitive performance. a likely basis of the nicotinic effects on cognitive functions is its effect on cortical excitability and activity. here, neurophysiological studies mainly base on animal experiments and have shown in vitro that the nicotinic acetylcholine receptors elicit neuronal depolarisation by inducing transmembrane cationic inward currents (calcium), thus being involved in induction and modulation of neuroplasticity and cortical excitability. repetitive transcranial magnetic stimulation: is a non-invasive brain stimulation technique that has shown positive results in the treatment of depression, schizophrenia, and more recently addiction. repetitive transcranial magnetic stimulation uses alternating magnetic fields to induce electric currents in the cortical tissue. low-frequency as one hertz repetitive transcranial magnetic stimulation is believed to inhibit neuronal firing in a localized area and is used to induce virtual brain lesions. high-frequency as more than three hertz repetitive transcranial magnetic stimulation is believed to be excitatory in nature and can result in neuronal depolarization under the stimulating coil. however, the effects of repetitive transcranial magnetic stimulation are not limited to the site of stimulation and can induce changes in distant interconnected sites of the brain, and consequently may influence subcortical regions.

Eligibility criteria:
inclusion criteria: 1 )patients must be 18 to 50 years of age. 2) heavy smokers (daily cigarettes consumption of more than 20 pieces.) exclusion criteria: 1. cardiac pacemaker. 2. metal implants in the head. 3. renal diseases
gastric preparation of magnetic-controlled capsule endoscopy

Conditions: Stomach Diseases

Summary: by using three different gastric preparation of magnetic-controlled capsule endoscopy, the investigators hope to find out the optimal gastric preparation plan.

it is a prospective, single-blind, randomized controlled trial. patients who were conducted by magnetic-controlled capsule endoscopy at changhai hospital will be randomly allocated into three different gastric preparation group before the procedure. it include clear water group which patient only drink 1000ml clear water before checking; simethicone group which patient drink 950ml clear water and 15ml simethicone before checking; simethicone combined with pronase group which patient drink 900ml lear water and 15ml simethicone and 20，000iu pronase before checking. the result were got from a relevant professional physician's blinded independent image-reading.

Eligibility criteria:
inclusion criteria: * adult patients aged 16-75 years, who were scheduled to undergo a magnetic-controlled capsule endoscopy, were eligible for this study. exclusion criteria: * dysphagia or symptoms of gastric outlet obstruction, suspected or known intestinal stenosis, overt gastrointestinal bleeding, history of upper gastrointestinal surgery or abdominal surgery altering gastrointestinal anatomy, or postabdominal radiation; * congestive heart failure, renal insufficiency, under therapeutic anticoagulation, in poor general condition (american society of anesthesiologists class iii/iv), claustrophobia, metallic parts, a pacemaker or other implanted electromedical devices, artificial heart valves; * pregnancy or suspected pregnancy; * exclusion criteria for standard magnetic resonance imaging (mri) examination such as the presence of surgical metallic devices, even though its low magnetic field would technically not interfere with such devices; * currently participating in another clinical study.

Keywords: preparation capsule endoscopy